Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05078775 · ClinicalTrials.gov registry record · NA

Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

A NA study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Unresectable Pancreatic Adenocarcinoma, sponsored by Faeth Therapeutics.

Completed
Registry status
NA
Development phase
39
Enrollment target
9
Study locations

NCT05078775 is a NA study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Unresectable Pancreatic Adenocarcinoma that has completed, run by Faeth Therapeutics. The registered enrollment target is 39 participants, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (56% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05078775, a NA study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Unresectable Pancreatic Adenocarcinoma, has completed, sponsored by Faeth Therapeutics.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
9
Study locations

Study Summary

This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.

Interventions

  • OTHER NEAAR Medical Food

Study Locations (9)

California

  • Oncology Physicians Network - Glendale
  • Cedars-Sinai - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach

Arizona

  • University of Arizona Cancer Center - Tucson

Florida

  • Florida Cancer Specialists - Fort Myers

New Jersey

  • Atlantic Health - Morristown

North Carolina

  • xCures - Virtual Site - Raleigh

Tennessee

  • Sarah Cannon - Nashville

Texas

  • Baptist Hospitals of Southeast Texas - Beaumont

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2021-12-21
Est. Completion 2025-07-10
Phase NA

Sponsor

Faeth Therapeutics

5 total trials

What the Registry Record Tells You About NCT05078775

The ClinicalTrials.gov registry entry for NCT05078775 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (56% lower). The listed sponsor is Faeth Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which NEAAR Medical Food is the first listed.

NCT05078775 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT05078775 about?

NCT05078775 is a clinical study titled "Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer". This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are el...

What is the current status of trial NCT05078775?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2021-12-21. Estimated completion is 2025-07-10.

What conditions does trial NCT05078775 study?

This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT05078775?

The interventions under investigation include: NEAAR Medical Food (OTHER).

Who is sponsoring clinical trial NCT05078775?

This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05078775 being conducted?

This trial has 9 study locations across Arizona, California, Florida, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.